BioCentury | Dec 23, 2017
Regulation

Prioritizing preferences

...CDRH granted the first-ever product approval that was based on a patient preference study -- ReShape Lifesciences Inc.’s...
...Institute, Santa Monica, Calif. Parent Project Muscular Dystrophy (PPMD), Hackensack, N.J. PatientsLikeMe Inc., Cambridge, Mass. ReShape Lifesciences Inc....
BioCentury | Jan 20, 2017
Financial News

EnteroMedics completes follow-on

...On Jan. 18, metabolic medical device company EnteroMedics Inc. (NASDAQ:ETRM) raised $16.5 million through the sale...
...warrants to purchase up to 188 shares at $5.84. EnteroMedics Inc. (NASDAQ:ETRM), St. Paul, Minn. Alex Himes ReShape Lifesciences Inc....
BioCentury | Sep 26, 2016
Financial News

EnteroMedics proposes follow-on

EnteroMedics Inc. (NASDAQ:ETRM), St. Paul, Minn. Business: Endocrine/Metabolic Date announced: 2016-09-20 Type: Follow-on To be raised: Up to $5.8 million Units: TBD Price prior: $0.14 Underwriter: Ladenburg Thalmann Note: Each class A unit comprises two...
BioCentury | Sep 7, 2016
Company News

Management tracks

...of business development and alliance management at bluebird bio Inc. (NASDAQ:BLUE). CNS and metabolic company EnteroMedics...
BioCentury | Jul 26, 2016
Politics & Policy

FDA unveils draft guidance on real-world evidence for devices

...decisions. Last year, CDRH used patient preference data to approve the Maestro Rechargeable System from EnteroMedics...
BioCentury | Apr 22, 2016
Company News

Management tracks

...relations at Gruenenthal Group (Aachen, Germany) and SVP of government relations and health policy at EnteroMedics...
BioCentury | Dec 21, 2015
Strategy

Preferential practices

...has been approved based on data from patient preference studies. The Maestro Rechargeable System from EnteroMedics...
...and PPMD's activities," said Boutin. Companies and Institutions Mentioned Biotechnology Industry Organization (BIO), Washington, D.C. EnteroMedics...
BioCentury | Nov 9, 2015
Financial News

EnteroMedics proposes private placement of convertible notes and warrants

...$25 million Shares outstanding prior: 106.4 million Placement agent: Northland Securities Investor: Institutional investors Note: EnteroMedics...
BioCentury | Sep 7, 2015
Strategy

Back to School 2015: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
BioCentury | Jun 29, 2015
Product Development

Would you rather?

...short of a patient-reported outcome." Companies and Institutions Mentioned Biotechnology Industry Organization (BIO), Washington, D.C. EnteroMedics...
...preference survey it had commissioned to approve an obesity device, the Maestro Rechargeable System from EnteroMedics...
Items per page:
1 - 10 of 41
BioCentury | Dec 23, 2017
Regulation

Prioritizing preferences

...CDRH granted the first-ever product approval that was based on a patient preference study -- ReShape Lifesciences Inc.’s...
...Institute, Santa Monica, Calif. Parent Project Muscular Dystrophy (PPMD), Hackensack, N.J. PatientsLikeMe Inc., Cambridge, Mass. ReShape Lifesciences Inc....
BioCentury | Jan 20, 2017
Financial News

EnteroMedics completes follow-on

...On Jan. 18, metabolic medical device company EnteroMedics Inc. (NASDAQ:ETRM) raised $16.5 million through the sale...
...warrants to purchase up to 188 shares at $5.84. EnteroMedics Inc. (NASDAQ:ETRM), St. Paul, Minn. Alex Himes ReShape Lifesciences Inc....
BioCentury | Sep 26, 2016
Financial News

EnteroMedics proposes follow-on

EnteroMedics Inc. (NASDAQ:ETRM), St. Paul, Minn. Business: Endocrine/Metabolic Date announced: 2016-09-20 Type: Follow-on To be raised: Up to $5.8 million Units: TBD Price prior: $0.14 Underwriter: Ladenburg Thalmann Note: Each class A unit comprises two...
BioCentury | Sep 7, 2016
Company News

Management tracks

...of business development and alliance management at bluebird bio Inc. (NASDAQ:BLUE). CNS and metabolic company EnteroMedics...
BioCentury | Jul 26, 2016
Politics & Policy

FDA unveils draft guidance on real-world evidence for devices

...decisions. Last year, CDRH used patient preference data to approve the Maestro Rechargeable System from EnteroMedics...
BioCentury | Apr 22, 2016
Company News

Management tracks

...relations at Gruenenthal Group (Aachen, Germany) and SVP of government relations and health policy at EnteroMedics...
BioCentury | Dec 21, 2015
Strategy

Preferential practices

...has been approved based on data from patient preference studies. The Maestro Rechargeable System from EnteroMedics...
...and PPMD's activities," said Boutin. Companies and Institutions Mentioned Biotechnology Industry Organization (BIO), Washington, D.C. EnteroMedics...
BioCentury | Nov 9, 2015
Financial News

EnteroMedics proposes private placement of convertible notes and warrants

...$25 million Shares outstanding prior: 106.4 million Placement agent: Northland Securities Investor: Institutional investors Note: EnteroMedics...
BioCentury | Sep 7, 2015
Strategy

Back to School 2015: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
BioCentury | Jun 29, 2015
Product Development

Would you rather?

...short of a patient-reported outcome." Companies and Institutions Mentioned Biotechnology Industry Organization (BIO), Washington, D.C. EnteroMedics...
...preference survey it had commissioned to approve an obesity device, the Maestro Rechargeable System from EnteroMedics...
Items per page:
1 - 10 of 41